Home >
Medicine Info >
Debrit 250 mg Tablet
Loading interface...

Debrit 250 mg Tablet

Manufactured byPfizer Ltd.
ContainsGefitinib
Description
Debrit 250 mg Tablet is an anticancer medicine which is used in the treatment of cancer of the lungs. It should only be used under the supervision of a qualified physician. This medicine is not recommended for use in patients with lung and liver diseases.
QUICK LINKS:
Side effectsConcernsUsage

Substitutes

List of substitutes for Debrit 250 mg Tablet

Denrit 250 mg Tablet
Pfizer Ltd.
Emfib 250 mg Tablet
Emcure Pharmaceuticals Ltd.
Geffon 250 mg Tablet
Zydus Cadila
Tyrogef 250 mg Tablet
Sun Pharma Laboratories Ltd.
Zefotib 250 mg Tablet
Alkem Laboratories Ltd.

Side effects

Major & minor side effects for Debrit 250 mg Tablet

  • Diarrhea
  • Fever
  • Allergic skin reaction
  • Nausea and Vomiting
  • Increase in liver enzyme levels
  • Eye irritation
  • Difficulty in breathing
  • Abdominal pain
  • Sore throat
  • Redness around fingernails

Uses of Debrit 250 mg Tablet

What is it prescribed for?

  • Non-Small Cell Lung Cancer
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The time taken for the medicine to show its effect is not clinically established. This medicine requires 3 to 7 hours to reach maximum concentration in the blood and it takes multiple dosing schedules to show its effect.
  • How long do the effects of this medicine last?
    After multiple dosing schedules, the time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. If this medicine is prescribed, your doctor will advise you to discontinue breastfeeding.

Allergy

This medicine is not recommended for use in patients with a known allergy to Debrit 250 mg Tablet.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. If this medicine is prescribed, your doctor will advise you to discontinue breastfeeding.
General warnings

Skin reactions

Patients receiving Debrit 250 mg Tablet have experienced severe skin reactions like toxic epidermal necrolysis, Stevens Johnson syndrome, and erythema multiforme. Close monitoring of symptoms like change in color of the skin, skin rashes, itching, blistering, etc. is necessary while receiving this medicine. Any such symptoms should be reported to the doctor on priority. The treatment should be discontinued if these symptoms appear.

Missed Dose

Take the missed dose as soon as you remember. Skip the missed dose if the time remaining for your next dose is less than 12 hours. Do not double your dose to make up for the missed dose.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Carbamazepine

Clarithromycin

Itraconazole

Phenytoin

Pantoprazole

Disease interactions

Lung disease

This medicine should be used with caution due to the risk of lung injury. Inform the doctor if you have any history of lung disease before receiving this medicine. The treatment should be discontinued if any symptoms of lung dysfunction appear.

Eye disorder

This medicine should be used with caution in patients with eye disorders like conjunctivitis or keratitis due to an increase in the risk of worsening symptoms. Inform the doctor if you have any history of eye disease before receiving this medicine. The treatment should be discontinued if symptoms worsen.

Gastrointestinal perforations

This medicine should be used with extreme caution due to an increase in the risk of gastrointestinal disorders like diarrhea, vomiting, and perforation. The risk is especially higher in patients with a history of gastrointestinal diseases. The treatment should be immediately discontinued in patients who develop gastrointestinal perforation.

Liver Disease

This medicine is not recommended for use in patients with a severe liver disease. In patients with mild to moderate liver disease, close monitoring of liver function is necessary. The treatment should be discontinued if there is worsening of the liver function.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take Debrit 250 mg Tablet as instructed by the doctor. Do not consume larger quantities than prescribed. It should be used as prescribed by the doctor to prevent the spread of cancer to other parts of the body. Discontinue the treatment if any symptoms of allergic skin reactions appear.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

Does not cause sleepiness

How it works
It works by blocking certain chemicals that are required for the growth of cancer cells.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

EGFR inhibitors

Schedule

Schedule H

[Internet]. 2017 [cited 21 July 2017]. Available from:

https://www.medicines.org.uk/emc/medicine/22104

Gefitinib: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 21 July 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a607002.html

DailyMed - gefitinib tablet, coated [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 21 July 2017]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41

Gefitinib - DrugBank [Internet]. Drugbank.ca. 2017 [cited 21 July 2017]. Available from:

https://www.drugbank.ca/drugs/DB00317

Prescribing medicines in pregnancy database [Internet]. Therapeutic Goods Administration (TGA). 2017 [cited 21 July 2017]. Available from:

https://www.tga.gov.au/prescribing-medicines-pregnancy-database

[Internet]. Toxnet.nlm.nih.gov. 2017 [cited 21 July 2017]. Available from:

https://toxnet.nlm.nih.gov/cgi-bin/sis/search2
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 5 Jan 2018

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.